NOVELIXHealthcare Research, Analytics & Technology
NOVELIX PHARMACEUTICALS LIMITE — PE Ratio & Valuation Analysis
₹55.78
-3.48%
Current P/E104.85xPrice to earnings
Industry P/E45.95xSector average
4Y Avg P/E2415.0x95.7% below avg
⚠️
128.2% Premium to Industry
NOVELIX P/E 104.85x vs sector avg 45.95x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2024 | ₹0.01 | ₹24 | 2415x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding NOVELIX PHARMACEUTICALS LIMITE Valuation
NOVELIX PHARMACEUTICALS LIMITE (NOVELIX) currently trades at 104.85x earnings. The Healthcare Research, Analytics & Technology sector average PE is 45.95x. NOVELIX commands a premium, reflecting high growth expectations. Historically, NOVELIX has traded at an average PE of 2415.0x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
0.64%
Dividend Yield
0.00%
More on NOVELIX PHARMACEUTICALS LIMITE
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.